Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Ovarian Cancer

Intensive sequential dose dense chemotherapy with stem cell support as first-line treatment in advanced ovarian carcinoma: a phase II study

Bone Marrow Transplantation volume 30, pages 879–884 (2002)Cite this article

Abstract

From August 1995 to December 1997, 15 patients with stage III–IV ovarian cancer were treated with outpatient intensive chemotherapy with G-CSF and stem cell support. The first cycle consisted of cyclophophamide IV 6 g/m2; second, third, fourth and fifth paclitaxel 250 mg/m2 and the sixth and seventh carboplatin AUC 18. CD34+ cells were collected after the first cycle and reinfused after completion of cycles 6 and 7. Fourteen patients had stage IIIc and one patient had stage IV disease with liver metastases. All patients underwent laparotomy to maximize tumor debulking. This was optimal in eight patients and suboptimal in seven patients. Second-look surgery was performed in 14 patients. All patients had macroscopic complete responses and 10 patients had complete histologic response. Median follow-up was 48 months (range, 20 to 62). Twelve patients had further progression at a median of 27 months (range, 9 to 42) and nine are alive, three without evidence of disease progression. This pilot study shows that dose-dense chemotherapy with paclitaxel and carboplatin is associated with low toxicity and may improve the outcome of patients with poor prognosis ovarian cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Cannistra S . Cancer of the ovary New Engl J Med 1993 329: 1550 1559

    Article  CAS  PubMed  Google Scholar 

  2. Gershenson DM, Copeland LJ, Wharton JT et al. Prognosis of surgically determined complete responders in advanced ovarian cancer Cancer 1985 55: 1129 1135

    Article  CAS  PubMed  Google Scholar 

  3. Omura GA, Bundy BN, Berek JS et al. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group study J Clin Oncol 1989 7: 457 465

    Article  CAS  PubMed  Google Scholar 

  4. Neijt JP, ten Bokkel Huinink WW, van der Burg M et al. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 vs CP) in advanced ovarian carcinoma J Clin Oncol 1987 5: 1157 1168

    Article  CAS  PubMed  Google Scholar 

  5. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer New Eng J Med 1996 334: 1 16

    Article  CAS  PubMed  Google Scholar 

  6. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results J Nat Cancer Inst 2000 92: 699 708

    Article  CAS  PubMed  Google Scholar 

  7. Behrens BC, Hamilton TC, Masuda H et al. Characterization of a cis-diamminechloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues Cancer Res 1987 47: 414 418

    CAS  PubMed  Google Scholar 

  8. Levin L, Hryniuk WM . Dose intensity analysis of chemotherapy regimens in ovarian carcinoma J Clin Oncol 1987 5: 756 767

    Article  CAS  PubMed  Google Scholar 

  9. Levin L, Simon R, Hryniuk W . Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis J Natl Cancer Inst 1993 85: 1732 1742

    Article  CAS  PubMed  Google Scholar 

  10. Dauplat J, Legos M, Condat J et al. High-dose melphalan and autologous bone marrow support for treatment of ovarian carcinoma with positive second-look operation Gynecol Oncol 1989 34: 294 298

    Article  CAS  PubMed  Google Scholar 

  11. Bertucci F, Viens P, Delpero JR et al. High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advanced ovarian carcinoma: long-term results Bone Marrow Transplant 2000 26: 61 67

    Article  CAS  PubMed  Google Scholar 

  12. Viens P, Maraninchi D, Legros M et al. High dose melphalan and autologous marrow rescue in advanced epithelial ovarian carcinomas: a retrospective analysis of 35 patients treated in France Bone Marrow Transplant 1990 5: 227 233

    CAS  PubMed  Google Scholar 

  13. Legros M, Dauplat J, Fleury J et al. High-dose chemotherapy with hematopoietic rescue in patients with stage III or IV ovarian cancer: long-term results J Clin Oncol 1997 15: 1302 1308

    Article  CAS  PubMed  Google Scholar 

  14. Stiff PJ, Bayer R, Kerger C et al. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients J Clin Oncol 1997 15: 1309 1317

    Article  CAS  PubMed  Google Scholar 

  15. Stoppa AM, Bouabdallah R, Chabannon C et al. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma J Clin Oncol 1997 15: 1722 1729

    Article  CAS  PubMed  Google Scholar 

  16. Schilder RJ, Johnson S, Gallo J et al. Phase I trial of multiple cycles of chemotherapy supported by autologous peripheral-blood stem cells J Clin Oncol 1999 17: 2198 2207

    Article  CAS  PubMed  Google Scholar 

  17. Aghajanian C, Fennely D, Shapiro F et al. Phase II study of ‘dose-dense’ high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer J Clin Oncol 1998 16: 1852 1860

    Article  CAS  PubMed  Google Scholar 

  18. Norton L . Kinetic concepts in the systemic drug therapy of breast cancer Semin Oncol 1999 26: 11 20

    CAS  PubMed  Google Scholar 

  19. Budman D, Berry DA, Cirrincione CT et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B J Natl Cancer Inst 1998 19: 1205 1211

    Article  Google Scholar 

  20. Chatelut E, Canal P, Brunner V et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics J Nat Cancer Institute 1995 87: 573 580

    Article  CAS  Google Scholar 

  21. Chabannon C, Le Coroller AG, Faucher C et al. Patient condition affects the collection of peripheral blood progenitors after priming with recombinant granulocyte colony-stimulating factor J Hematother 1995 4: 171 179

    Article  CAS  PubMed  Google Scholar 

  22. Kaplan EL, Meier P . Non parametric estimation from incomplete observations J Am Stat Assoc 1971 53: 457 481

    Article  Google Scholar 

  23. Pierelli L, Perillo A, Greggi S et al. Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a randomized comparison J Clin Oncol 1999 17: 1288 1295

    Article  CAS  PubMed  Google Scholar 

  24. Reiffers J, Cailliot C, Dazey B et al. Abrogation of post-myeloablative chemotherapy neutropenia by ex vivo expanded autologous CD34-positive cells Lancet 1999 354: 1092 1093

    Article  CAS  PubMed  Google Scholar 

  25. Berek J . Epiththelial ovarian cancer In: Berek JS, Hacker NF (eds) Practical Gynecologic Oncology William & Wilkins: Baltimore 1994 pp 327 382

    Google Scholar 

  26. Rubin S, Randall T, Armstrong K et al. Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings Obstet Gynecol 1999 93: 21 24

    CAS  PubMed  Google Scholar 

  27. Wandt H, Birkmann J, Denzel T et al. Sequential cycles of high-dose chemotherapy with escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: a phase I/II study in advanced ovarian cancer Bone Marrow Transplant 1999 23: 763 770

    Article  CAS  PubMed  Google Scholar 

  28. Fennelly D, Schneider J, Spriggs D et al. Dose escaladation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses J Clin Oncol 1995 13: 1160 1166

    Article  CAS  PubMed  Google Scholar 

  29. Cure H, Battista C, Guastalla J et al. Phase III randomized trial of high-dose chemotherapy and peripheral blood stem cell support as consolidation in patients with responsive low-burden advanced ovarian cancer: preliminary results of a GINECO/FNCLCC/ SFGM-TC study Proc Am Soc Clin Oncol 2001 20: 204a (Abstr. 815)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology Department, Cellular Therapy Department, Surgery Department, Institut Paoli-Calmettes, Marseille, France

    F Viret, F Bertucci, D Genre, G Gravis, C Chabannon, G Houvenaeghel, D Maraninchi & P Viens

  2. Hôpital Ambroise Paré, Marseille, France

    M Conte

  3. University Méditerranée, Marseille, IFR57, France

    F Bertucci, G Houvenaeghel, D Maraninchi & P Viens

Authors
  1. F Viret
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F Bertucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D Genre
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G Gravis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C Chabannon
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Conte
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G Houvenaeghel
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D Maraninchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. P Viens
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Viret, F., Bertucci, F., Genre, D. et al. Intensive sequential dose dense chemotherapy with stem cell support as first-line treatment in advanced ovarian carcinoma: a phase II study. Bone Marrow Transplant 30, 879–884 (2002). https://doi.org/10.1038/sj.bmt.1703762

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703762

Keywords

This article is cited by

Search

Advanced search

Quick links